Видео ютуба по тегу Belite Bio

Belite Bio | Nathan Mata, PhD, Chief Scientific Officer
Belite Bio | Nathan Mata, PhD, Chief Scientific Officer
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Belite Bio - Innovation Showcase at Ophthalmology Innovation Summit @ ASRS 2019
Belite Bio - Innovation Showcase at Ophthalmology Innovation Summit @ ASRS 2019
Belite Bio, Inc. BLTE: презентация финансовых результатов за третий квартал 2025 г.
Belite Bio, Inc. BLTE: презентация финансовых результатов за третий квартал 2025 г.
Belite Bio Clinical Trials Zoom Session
Belite Bio Clinical Trials Zoom Session
Belite Bio (Nasdaq: BLTE): Treating the untreatable eye diseases
Belite Bio (Nasdaq: BLTE): Treating the untreatable eye diseases
Belite Bio H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | Aug 13, 2025
Belite Bio H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | Aug 13, 2025
Inside Belite Bio: Advancing Hope for Stargardt Disease
Inside Belite Bio: Advancing Hope for Stargardt Disease
Belite Bio Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease
Belite Bio Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease
Belite Bio Q2 2025 Earnings Call | Q2 2025 Earnings Conference Call | Q2 2025 Results
Belite Bio Q2 2025 Earnings Call | Q2 2025 Earnings Conference Call | Q2 2025 Results
Belite Bio BLTE: презентация финансовых результатов за второй квартал 2025 года
Belite Bio BLTE: презентация финансовых результатов за второй квартал 2025 года
Belite Bio to speed up development of its incurable blindness treatment following NASDAQ listing
Belite Bio to speed up development of its incurable blindness treatment following NASDAQ listing
Belite Bio (BLTE|$3.6B) - 2025 Q3 Earnings Analysis
Belite Bio (BLTE|$3.6B) - 2025 Q3 Earnings Analysis
Stargardts Connected Conference 2024
Stargardts Connected Conference 2024
Belite Bio (BLTE|$2.3B) - 2025 Q2 Earnings Analysis
Belite Bio (BLTE|$2.3B) - 2025 Q2 Earnings Analysis
BLTE, Belite Bio, Inc, stock prices dynamics, stock of the day #BLTE
BLTE, Belite Bio, Inc, stock prices dynamics, stock of the day #BLTE
Belite Bio (BLTE|$2.0B) - 2024 Full Year Earnings Analysis
Belite Bio (BLTE|$2.0B) - 2024 Full Year Earnings Analysis
Belite Bio (BLTE|$2.0B) - 2025 Q1 Earnings Analysis
Belite Bio (BLTE|$2.0B) - 2025 Q1 Earnings Analysis
BLTE: Belite Bio, Inc - stock prices historical data
BLTE: Belite Bio, Inc - stock prices historical data
BLTE, Belite Bio, Inc, 2025-12-01, stock prices dynamics, stock of the day
BLTE, Belite Bio, Inc, 2025-12-01, stock prices dynamics, stock of the day